Botulinum Toxin Type A: Mechanism of Action

Botulinum toxin type A (BoNT-A) is a neurotoxic protein produced by the bacterium Clostridium botulinum. In aesthetic medicine, purified BoNT-A is injected in micro-doses to temporarily block acetylcholine release at the neuromuscular junction. This causes targeted muscle relaxation without affecting surrounding tissues. The effect is dose-dependent and reversible, typically lasting 3-6 months depending on the treatment area, individual metabolism, and product used. The mechanism was first described by Burgen et al. (1949) and has been extensively studied over seven decades, making BoNT-A one of the most well-characterized therapeutics in medicine. For cosmetic applications, Scott (1980) pioneered its use for strabismus treatment, leading to its eventual FDA approval for aesthetic indications in 2002. Today, BoNT-A is approved for cosmetic use in over 90 countries, with an estimated 6+ million treatments performed annually worldwide.

Korea’s Nabota: A Breakthrough in Domestic Manufacturing

Nabota (letibotulinumtoxinA), manufactured by Daewoong Pharmaceutical in South Korea, represents a significant milestone in the globalization of botulinum toxin production. Approved by the KFDA in 2013, Nabota was the first Korean-made BoNT-A product to receive international regulatory approvals, now marketed in over 50 countries. The pivotal Phase III clinical trial published by Won et al. (2016) in the Journal of Dermatological Treatment demonstrated non-inferiority to Allergan Botox (onabotulinumtoxinA) for the treatment of moderate-to-severe glabellar frown lines. The study reported a 93.3% responder rate at week 4, comparable to the reference product. Daewoong’s proprietary manufacturing process uses a unique strain of C. botulinum type A (Hall strain) and a patented purification method that maintains high specific activity. The result is a product with consistent potency, reliable clinical performance, and a safety profile equivalent to established international brands. For patients at RE:BERRY Myeongdong, Nabota offers an optimal balance of efficacy and value, backed by rigorous clinical data.

Xeomin: The Pure Neurotoxin Advantage

Xeomin (incobotulinumtoxinA) by Merz Aesthetics distinguishes itself through a unique manufacturing process that removes complexing proteins from the botulinum toxin molecule. Traditional BoNT-A products contain these proteins as part of the natural toxin complex, but Frevert (2015) demonstrated in Drugs in R&D that the complexing proteins dissociate rapidly under physiological conditions and do not contribute to clinical efficacy. The theoretical advantage of Xeomin’s pure formulation is reduced immunogenicity — a lower risk of the body developing neutralizing antibodies that could diminish treatment effectiveness over time. This is particularly relevant for patients who undergo frequent, long-term botox treatments. A multicenter study by Sattler et al. (2010) in the Journal of Neural Transmission confirmed Xeomin’s equivalent clinical efficacy to Allergan Botox while noting no secondary treatment failures due to antibody formation in the study population.

Volume-Based Expertise: The Korean Advantage

A 2023 analysis published in the Journal of Cosmetic Dermatology by Park et al. examined the correlation between practitioner injection volume and patient outcomes. The study found that physicians performing more than 500 BoNT-A treatments annually achieved statistically significantly higher patient satisfaction scores and lower complication rates compared to those performing fewer than 100 treatments. Korean aesthetic doctors, particularly those in high-traffic districts like Myeongdong and Gangnam, routinely exceed 1,000 treatments annually. This volume-expertise relationship explains why Korean botox outcomes are consistently ranked among the best globally, and why clinics like RE:BERRY Myeongdong can maintain both high quality and competitive pricing.

References: Carruthers A, Carruthers J. Dermatol Surg. 2004;30(2):S12-S17. doi:10.1111/j.1524-4725.2004.30002.x | Jankovic J. Toxicon. 2004;44(2):147-152. doi:10.1016/j.toxicon.2004.04.028 | Klein AW. J Am Acad Dermatol. 2004;51(1):S21-S28. doi:10.1016/j.jaad.2004.01.018